Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.43 |
| ▸ | ACHE | P22303 | 3/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 2/20 | 0.40 |
| ▸ | CA2 | P00918 | 2/20 | 0.40 |
| ▸ | CA7 | P43166 | 2/20 | 0.40 |
| ▸ | CA9 | Q16790 | 2/20 | 0.40 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.39 |
| ▸ | MAOA | P21397 | 2/20 | 0.38 |
| ▸ | BCHE | P06276 | 4/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.36 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.36 |
| ▸ | NOX1 | Q9Y5S8 | 2/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8051363 | 0.93 | — | — | |
| SCHEMBL3419815 | 0.93 | MEN1 (0.47) | MEN1KMT2AALOX5ACHETSHR | |
| SCHEMBL3423172 | 0.90 | CA1 (0.43) | MEN1KMT2AALOX5ACHETSHR | |
| SCHEMBL3423894 | 0.84 | MEN1 (0.37) | MEN1KMT2AALOX5ACHECA1 | |
| SCHEMBL3423176 | 0.84 | MEN1 (0.37) | MEN1KMT2AALOX5ACHECA1 | |
| SCHEMBL3422316 | 0.82 | MEN1 (0.43) | MEN1KMT2AALOX5ACHETSHR | |
| O-Xylene SCHEMBL28671014 | 0.82 | ACHE (0.62) | MEN1KMT2AACHETSHRCA1 | |
| SCHEMBL9804804 | 0.79 | ALOX5 (0.38) | MEN1KMT2AALOX5ACHETSHR | |
| SCHEMBL18267880 | 0.78 | MEN1 (0.43) | MEN1KMT2AALOX5TSHRGPR84 | |
| SCHEMBL19765303 | 0.77 | ALOX5 (0.57) | MEN1KMT2AALOX5GPR84MAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 121 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170062842-A1 | TWO-ELECTRON REDOX ACTIVE MOLECULES WITH HIGH CAPACITY AND ENERGY DENSITY FOR ENERGY STORAGE APPLICATIONS | UCHICAGO ARGONNE, LLC | 2017-03-02 | — | — | US | claimed |
| US-11890296-B2 | Anti-tumor agent containing cytarabine, anti- tumor effect enhancing agent which is used in combination with cytarabine, anti-tumor kit, and anti-tumor agent which is used in combination with cytarabine | FUJIFILM CORPORATION (JP) | 2024-02-06 | — | — | US | disclosed |
| WO-2023219521-A1 | NEW 2-(DIETHYLAMINO)-4,6-DIPHENYLBENZENE-1,3-CARBONITRILE DERIVATIVES, METHOD OF THEIR PRODUCTION, THEIR USE AND NEW PHOTOINITIATING SYSTEMS FOR PHOTOINITIATED CATIONIC, RADICAL, THIOL-ENE AND HYBRID POLYMERIZATION | Politechnika Krakowska im. Tadeusza Kościuszki (PL) | 2023-11-16 | — | — | WO | disclosed |
| US-11795387-B2 | Metal-assisted delayed fluorescent materials as co-host materials for fluorescent OLEDs | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2023-10-24 | — | — | US | disclosed |
| EP-3131897-B1 | FACTOR IXA INHIBITORS | MERCK SHARP & DOHME (US) | 2022-06-15 | — | — | EP | disclosed |
| US-11217758-B2 | Organic light-emitting device | SAMSUNG DISPLAY CO., LTD. (KR) | 2022-01-04 | — | — | US | disclosed |
| EP-3858361-A1 | ANTITUMOR AGENT CONTAINING CYTARABINE, ANTITUMOR EFFECT ENHANCER USED IN COMBINATION WITH CYTARABINE, ANTITUMOR KIT, AND ANTITUMOR AGENT USED IN COMBINATION WITH CYTARABINE | FUJIFILM Corporation (JP) | 2021-08-04 | — | — | EP | disclosed |
| US-20210213040-A1 | ANTI-TUMOR AGENT CONTAINING CYTARABINE, ANTI-TUMOR EFFECT ENHANCING AGENT WHICH IS USED IN COMBINATION WITH CYTARABINE, ANTI-TUMOR KIT, AND ANTI-TUMOR AGENT WHICH IS USED IN COMBINATION WITH CYTARABINE | FUJIFILM CORPORATION (JP) | 2021-07-15 | — | — | US | disclosed |
| US-20210135128-A1 | PHOTOELECTRIC CONVERSION ELEMENT, IMAGING ELEMENT, OPTICAL SENSOR, AND COMPOUND | FUJIFILM CORPORATION (JP) | 2021-05-06 | — | — | US | disclosed |
| US-10937971-B2 | Organic monomolecular white light material, manufacturing method for the same, and OLED element | SHENZHEN CHINA STAR OPTOELECTRONICS TECHNOLOGY CO., LTD. (CN) | 2021-03-02 | — | — | US | disclosed |
| US-20090036501-A1 | 2-Cyclopenten-1-One Oxime Derivatives Inhibiting Production of TNF-Alpha | AMOREPACIFIC CORPORATION (KR) | 2009-02-05 | — | — | US | disclosed |
| US-20080280910-A1 | PHTHALAZINONE DERIVATIVES | KUDOS PHARMACEUTICALS LIMITED (GB) | 2008-11-13 | — | — | US | disclosed |
| US-20080280910-A1 | PHTHALAZINONE DERIVATIVES | KUDOS PHARMACEUTICALS LIMITED (GB) | 2008-11-13 | — | — | US | disclosed |
| US-20070272920-A1 | Metal quinolate, in particular lithium quinolate, and an electroluminescent organometallic thianthrene ligand complex; displays in video displays, mobile telephones, portable computers | MERCK PATENT GMBH (DE) | 2007-11-29 | — | — | US | disclosed |
| US-20070099186-A1 | Methods and means for the treatment of disorders associated with cellular senescence | KUDOS PHARMACEUTICALS LIMITED (GB) | 2007-05-03 | — | — | US | disclosed |
| US-20070099186-A1 | Methods and means for the treatment of disorders associated with cellular senescence | KUDOS PHARMACEUTICALS LIMITED (GB) | 2007-05-03 | — | — | US | disclosed |
| WO-2005021529-A1 | BIPYRIDYL AMINES AND ETHERS AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 | MERCK & CO., INC. (US) | 2005-03-10 | — | — | WO | disclosed |
| US-4190609-A | USING A LEWIS ACID CATALYST AND A THIANTHRENE COCATA6YST | HOOKER CHEMICALS & PLASTICS CORP. (US) | 1980-02-26 | — | — | US | disclosed |
| US-4069263-A | Process for directed chlorination of alkylbenzenes | HOOKER CHEMICALS & PLASTICS CORPORATION (US) | 1978-01-17 | — | — | US | disclosed |
| US-4069264-A | CHLORINE, LEWIS ACID CATALYST, THIANTHRENE COMPOUND AS CO-CATALYST | HOOKER CHEMICALS & PLASTICS CORPORATION (US) | 1978-01-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170062842-A1 | TWO-ELECTRON REDOX ACTIVE MOLECULES WITH HIGH CAPACITY AND ENERGY DENSITY FOR ENERGY STORAGE APPLICATIONS | CYP11B1, CYP11B2, ESR2 | MEN1 4003/4885KMT2A 2147/4885ALOX5 1244/4885 |
| US-10937971-B2 | Organic monomolecular white light material, manufacturing method for the same, and OLED element | NLRP3, NLRP1, OCIAD1 | MEN1 2544/4885KMT2A 1622/4885ALOX5 243/4885 |
| US-11890296-B2 | Anti-tumor agent containing cytarabine, anti- tumor effect enhancing agent which is used in combination with cytarabine, anti-tumor kit, and anti-tumor agent which is used in combination with cytarabine | DHODH, DPYD, DCTD | MEN1 4227/4885KMT2A 1119/4885ALOX5 693/4885 |
| US-20080280910-A1 | PHTHALAZINONE DERIVATIVES | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, SDHA, NCOA4 | MEN1 413/4885KMT2A 2206/4885ALOX5 1794/4885 |
| US-20090036501-A1 | 2-Cyclopenten-1-One Oxime Derivatives Inhibiting Production of TNF-Alpha | TNF, PDE4A, PDE3B | MEN1 4114/4885KMT2A 4315/4885ALOX5 371/4885 |
| US-20070272920-A1 | Metal quinolate, in particular lithium quinolate, and an electroluminescent organometallic thianthrene ligand complex; displays in video displays, mobile telephones, portable computers | TRPM7, TRPM5, OXA1L | MEN1 204/4885KMT2A 2529/4885ALOX5 2348/4885 |
| US-20210213040-A1 | ANTI-TUMOR AGENT CONTAINING CYTARABINE, ANTI-TUMOR EFFECT ENHANCING AGENT WHICH IS USED IN COMBINATION WITH CYTARABINE, ANTI-TUMOR KIT, AND ANTI-TUMOR AGENT WHICH IS USED IN COMBINATION WITH CYTARABINE | DHODH, DPYD, DCTD | MEN1 4227/4885KMT2A 1119/4885ALOX5 693/4885 |
| US-20070099186-A1 | Methods and means for the treatment of disorders associated with cellular senescence | RAD1, TP53, CHEK2 | MEN1 1799/4885KMT2A 2675/4885ALOX5 3963/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.